

IN THE CLAIMS:

Claims 1-6, 8-48, and 50 were previously canceled. Claim 7 has been amended herein. Pending claims 7 and 49 are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of Claims:

1.-6. (Canceled)

7. (Currently amended) A method of inducing tolerance in an HA-1 negative, HLA-A2.1 positive subject to ~~prevent or~~ mitigate rejection of an HLA-matched graft and/or Graft versus Host disease, said method comprising:

repeatedly administering a tolerance-inducing dose of a peptide ~~with a length of between 9 and 15 amino acid residues and comprising a sequence~~ consisting of VLHDDLLEA (SEQ ID NO:2) to the subject.

8.-48. (Canceled).

49. (Previously presented) The method according to claim 7, wherein said peptide is administered orally, intravenously, intra-ocularly, or intranasally.

50. (Canceled).